OSA
5
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
ApnimedMA - Cambridge
5 programs2
3
AD109Phase 31 trial
AD109Phase 31 trial
Aroxybutynin and AtomoxetinePhase 31 trial
AD109Phase 21 trial
Period APhase 21 trial
Active Trials
+2 more trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
ApnimedAroxybutynin and Atomoxetine
ApnimedAD109
ApnimedAD109
ApnimedAD109
ApnimedPeriod A
Clinical Trials (5)
Continuation Protocol for Obstructive Sleep Apnea (OSA)
Start: Jul 2024Est. completion: Jun 2026
Phase 3Enrolling By Invitation
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
Start: Sep 2023Est. completion: Mar 2025
Phase 3Completed
Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)
Start: Aug 2023Est. completion: May 2025
Phase 3Completed
Study That Tests AD109 in Patients Taking GLP-1 Drugs
Start: May 2024Est. completion: Dec 2024
Phase 2Completed
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space